Evidence map›Paper›PMID 35326613›Full record

ReviewCancers2022

Towards a Molecular Classification of Sinonasal Carcinomas: Clinical Implications and Opportunities.

Cecilia Taverna, Abbas Agaimy, Alessandro Franchi

Open access · goldAbstract readReview
In one paragraph

Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
6.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Prognostic impact of immune-related adverse events in recurrent or metastatic sinonasal squamous cell carcinoma treated with immune checkpoint inhibitors.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026
    Article
  4. EGFR mutations in sinonasal squamous neoplasms: Novel hotspot for exon 20 insertions.Virchows Archiv : an international journal of pathology · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. [Sinonasal neoplasms: Update from the WHO 2022].Pathologie (Heidelberg, Germany) · 2023
    Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Cecilia TavernaDepartment of Translational Research and of New Technologies in Medicine and Surgery, University of Pisa, 56124 Pisa, Italy.ORCID 0000-0002-1253-550X
Abbas AgaimyInstitute of Pathology, Comprehensive Cancer Center (CCC) Erlangen-EMN, 91054 Erlangen, Germany.ORCID 0000-0002-0445-8161
Alessandro FranchiDepartment of Translational Research and of New Technologies in Medicine and Surgery, University of Pisa, 56124 Pisa, Italy.ORCID 0000-0002-1332-5838
University of Pisa · ITComprehensive Cancer Center Erlangen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sinonasal carcinomas are a heterogeneous group of rare tumors, often with high-grade and/or undifferentiated morphology and aggressive clinical course. In recent years, with increasing molecular testing, unique sinonasal tumor subsets have been identified based on specific genetic alterations, including protein expression, chromosomal translocations, specific gene mutations, or infection by oncogenic viruses. These include, among others, the identification of a subset of sinonasal carcinomas associated with HPV infection, the identification of a subset of squamous cell carcinomas with

Indexed as

molecular subtypingpathologysinonasal carcinomastumor classification

Identifiers

PMID35326613
PMCPMC8946109
OpenAlexW4221104552

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.